Bioventus Inc. cash flow to debt ratio of 23.76% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Bioventus Inc.'s free cash flow has increased 88.98% from $37.79M last year to $71.41M, signaling increasing performance

Bioventus Inc.'s debt to equity ratio is 1.44, which means that the company's assets are unhealthy financed, signaling financial risk. READ MORE: A ratio over 0.60 means the company finances its assets with debt, signaling financial risk. If ratio is negative, the company spent its own equity and risks bankruptcy

Bioventus Inc.'s debt has decreased relative to shareholder equity from 2.27 last year to 1.44 today, signaling strengthened financials

Bioventus Inc. has a net debt to EBITDA ratio of 2.62x, which is below the 3.00x threshold, indicating healthy leverage and financial stability

Bioventus Inc.'s interest coverage ratio of 2.63 indicates that earnings with margin can cover interest payments on company debt

Bioventus Inc.'s profit margin has increased (-184.47%) in the last year from -5.85% to 4.94%, signaling increasing performance

Bioventus Inc.'s short-term assets of $272.84M exceed its short-term liabilities of $160.38M

Bioventus Inc.'s return on assets of 4.38% is lower than the 5.00% threshold, indicating inefficient asset utilization

Bioventus Inc.'s return on equity of 16.27%, is higher than 15.00%, indicating good performance

Bioventus Inc.'s operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation

Bioventus Inc. had positive net income in only 2.00 out of 5 years, indicating unstable earnings

Bioventus Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

Bioventus Inc. has a free cash flow yield of 9.12%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

Bioventus Inc.'s yearly earnings has increased -167.77% since last year from $-33.54M to $22.73M, signaling increasing performance

Bioventus Inc.'s yearly revenue has decreased -0.91% since last year from $573.28M to $568.09M, signaling decreasing performance

ROIC 11.77% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.

Bioventus Inc.'s 3-year revenue CAGR of 3.52% is positive, indicating growing revenue over the past 3 years

Bioventus Inc. had revenue growth in 4.00 out of 5 years, indicating consistent revenue performance

Bioventus Inc. had positive ROE in only 2.00 out of 5 years, indicating inconsistent returns on equity

Bioventus Inc. is undervalued relative to its fair value price of 12.74 based on Discounted Cash Flow model

Bioventus Inc. has an earnings yield of 3.66%, which is below the 4.00% threshold, indicating the stock may be expensive relative to its earnings

Bioventus Inc. is overvalued relative to its fair value price of 7.11 based on EBITDA multiple model

Bioventus Inc. has an EV/EBITDA ratio of 10.52x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings

Bioventus Inc. is overvalued relative to its fair value price of -3.33 based on Earnings Fair Value model

Bioventus Inc. has a PEG-ratio under 1 which is considered undervalued

Bioventus Inc. has a price-to-book ratio of 3.32x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Bioventus Inc. has a price-to-sales ratio of 1.35x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue